Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ibogaine/Tobacco/Nicotine Use Disorder (TUD)

Ibogaine for Tobacco/Nicotine Use Disorder (TUD)

8 papers and 0 clinical trials exploring ibogaine as a treatment for tobacco/nicotine use disorder (tud).

CompoundIndole Alkaloid

Ibogaine

A unique indole alkaloid with complex pharmacology, investigated primarily for its capacity to interrupt substance use disorders and withdrawal.

Full Ibogaine profile
Indication1.3 billion smokers worldwide.

Tobacco/Nicotine Use Disorder (TUD)

Tobacco Use Disorder (TUD) presents significant challenges for public health, and emerging research indicates that psychedelic compounds may offer novel therapeutic avenues for treatment. Initial studies highlight the potential of psychedelics like ayahuasca and ibogaine in reducing tobacco dependence.

Full Tobacco/Nicotine Use Disorder (TUD) profile

Academic Research

8 papers
Paywallmeta

Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview

This review (2023) examines ibogaine as a potential treatment for substance use disorders (SUDs). The lack of randomised, controlled studies on its safety and efficacy and the elusive mechanisms of action have been barriers to clinical use. The review suggests that ibogaine and its metabolite, noribogaine (NOR), modulate multiple targets associated with SUDs, emphasizing a complex, multi-target approach to understanding its pharmacology.

Published
November 8, 2023
Journal
Journal of Psychopharmacology
Authors
Ona, G., Reverte, I., Rossi, G. N., Dos Santos, R. G., Hallak, J. E., Colomina, M. T., Bouso, J. C.
Paywallmeta

Do Hallucinogens Have a Role in the Treatment of Addictions? A Review of the Current Literature

This paper (2021) reviews the current literature regarding LSD, psilocybin, ketamine, ibogaine, and ayahuasca as potential treatments for addiction. The authors conclude that the available evidence is promising, but that more robust research is needed.

Published
March 31, 2021
Journal
SN Comprehensive Clinical Medicine
Authors
Nigam, K. B., Pandurangi, A. K.
Open Accessmeta

DARK Classics in Chemical Neuroscience: Ibogaine

This literature review (2018) of the history of ibogaine looks back at the early use, pharmacological studies, and subsequent clinical trials that investigate this compound for the treatment of mental health disorders.

Published
September 14, 2018
Journal
ACS Chemical Neuroscience
Authors
Wasko, M. J., Witt-Enderby, P. A., Surratt, C. K.
Paywallindividual

Ibogaine Acute Administration in Rats Promotes Wakefulness, Long-Lasting REM Sleep Suppression, and a Distinctive Motor Profile

This rat study (n=26) investigated the effects of ibogaine (20 and 40 mg/kg) on the states of sleep and wakefulness in rats and found that it promotes a waking state that was accompanied by a decrease in the total amount of SWS and REM sleep, in a similar pattern as traditional psychedelics.

Published
April 27, 2018
Journal
Frontiers in Pharmacology
Authors
Baumann, M. H., Carrera, I., Scorza, C., González, J., Prieto, J. P., Rodríguez, P., Cavelli, M., Benedetto, L., Mondino, A., Pazos, M., Seoane, G., Torterolo, P.
Open Accessmeta

Can psychedelic compounds play a part in drug dependence therapy?

The paper reviews renewed interest in psychedelic-assisted therapies for drug dependence, summarising emerging studies of psilocybin, ketamine, ibogaine and ayahuasca. Despite clinical and legal limitations, it argues that the potential to improve patient outcomes warrants further research.

Published
January 2, 2018
Journal
British Journal of Psychiatry
Authors
Sessa, B., Johnson, M. W.
Open Accessmeta

The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation

This review (2015) examines how the anti-addictive drug ibogaine affects the heart and the cardiovascular system and outlines a sequence of deleterious events that lower heart rate and selectively block cardiac ion channels which pave the way for life-threatening arrhythmias. Due to the longevity of noribogaine-ibogaine’s active metabolite-in human plasma, cardiac adverse events may also occur several days after, which highlights the need for developing less toxic variants of ibogaine such as 18-MC.

Published
January 29, 2015
Journal
Journal of Humanistic Psychology
Authors
Koenig, X., Hilber, K.

Clinical Trials

0 trials

No clinical trials have been tagged with both Ibogaine and Tobacco/Nicotine Use Disorder (TUD) yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Ibogaine papers Search all Tobacco/Nicotine Use Disorder (TUD) trials Full Ibogaine profile Full Tobacco/Nicotine Use Disorder (TUD) profile